Luteolin has been observed to inhibit the Janus kinase 2 (JAK2)/STAT3 signaling pathway in AD mouse model, along with reduced IL-17 expression and diminished Th17-mediated inflammatory responses (Tang et al., 2022). This evidence concerns the gene IL17A and Alzheimer disease.